Company:  NEOGENOMICS INC (NEO)
Form Type:  10-Q
Filing Date:  7/31/2020 
CIK:  0001077183 
Address:  12701 COMMONWEALTH DRIVE
SUITE 9
 
City, State, Zip:  FORT MYERS, Florida 33913 
Telephone:  (941) 923-1949 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$35.82  
Change: 
0.77 (2.20%)  
Trade Time: 
Sep 25  
Market Cap: 
$3.96B
Trade NEO now with

© 2020  
Description of Business
NeoGenomics, Inc., a Nevada corporation (referred to individually as the "Parent Company" or collectively with its subsidiaries as "NeoGenomics", "we", "us", "our" or the "Company" in this Annual Report) is the registrant for SEC reporting purposes. Our common stock is listed on the NASDAQ Capital Market under the symbol "NEO". Overview We operate a network of cancer-focused testing laboratories in the United States as well as laboratories in Switzerland and Singapore. Our mission is to improve patient care through exceptional cancer-focused testing services. Our vision is to be the World's leading cancer testing and information company by delivering uncompromising quality and innovative solutions while providing exceptional service and operating with a world-class culture.
Register and access this filing in:     
  FORM 10-Q
    PART I - FINANCIAL INFORMATION
      ITEM 1. FINANCIAL STATEMENTS
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ...
      ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 4. CONTROLS AND PROCEDURES
    PART II - OTHER INFORMATION
      ITEM 1. LEGAL PROCEEDINGS
      ITEM 1A. RISK FACTORS
      ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF ...
      ITEM 3. DEFAULTS UPON SENIOR SECURITIES
      ITEM 4. MINE SAFETY DISCLOSURES
      ITEM 5. OTHER INFORMATION
      ITEM 6. EXHIBITS
    SIGNATURES
  EXHIBIT 31.1
    CERTIFICATIONS
  EXHIBIT 31.2
    CERTIFICATIONS
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO